Previous Article | Next Article ![]()
Journal of Virology, August 2001, p. 7435-7452, Vol. 75, No. 16
Department of Microbiology and Immunology,
University of California, San Francisco, California
94143-04141; California Regional Primate
Research Center, Department of Pathology, School of
Medicine,2 and Department of
Pathology, Microbiology, and Immunology, School of Veterinary Medicine,
and Center for Comparative Medicine,3
University of California, Davis, California 95616; and
Retroviral Pathogenesis Laboratory, AIDS Vaccine Program,
SAIC Frederick, National Cancer Institute-Frederick Cancer Research
and Development Center, Frederick, Maryland
217024
Received 9 February 2001/Accepted 12 May 2001
Here we provide the first report of protection against a vaginal
challenge with a highly virulent simian immunodeficiency virus (SIV) by
using a vaccine vector. New poliovirus vectors based on Sabin 1 and 2 vaccine strain viruses were constructed, and these vectors were used to
generate a series of new viruses containing SIV gag,
pol, env, nef, and
tat in overlapping fragments. Two cocktails of 20 transgenic polioviruses (SabRV1-SIV and SabRV2-SIV) were inoculated
into seven cynomolgus macaques. All monkeys produced substantial
anti-SIV serum and mucosal antibody responses. SIV-specific cytotoxic
T-lymphocyte responses were detected in three of seven monkeys after
vaccination. All 7 vaccinated macaques, as well as 12 control macaques,
were challenged vaginally with pathogenic SIVmac251. Strikingly,
four of the seven vaccinated animals exhibited substantial protection
against the vaginal SIV challenge. All 12 control monkeys became SIV
positive. In two of the seven SabRV-SIV-vaccinated monkeys we found no
virological evidence of infection following challenge, indicating that
these two monkeys were completely protected. Two additional
SabRV-SIV-vaccinated monkeys exhibited a pronounced reduction in
postacute viremia to <103 copies/ml, suggesting that the
vaccine elicited an effective cellular immune response. Three of six
control animals developed clinical AIDS by 48 weeks postchallenge. In
contrast, all seven vaccinated monkeys remained healthy as judged by
all clinical parameters. These results demonstrate the efficacy of
SabRV as a potential human vaccine vector, and they show that the use
of a vaccine vector cocktail expressing an array of defined antigenic sequences can be an effective vaccination strategy in an outbred population.
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.16.7435-7452.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Protection against Simian Immunodeficiency Virus
Vaginal Challenge by Using Sabin Poliovirus Vectors
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, University of California, Box 0414, 513 Parnassus Ave., San Francisco, CA 94143-0414. Phone: (415) 502-7196. Fax: (415) 476-0939. E-mail: andino{at}itsa.ucsf.edu.
This article has been cited by other articles:
| J. Bacteriol. | Mol. Cell. Biol. | Microbiol. Mol. Biol. Rev. |
|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|